Benzinga's Top Upgrades, Downgrades For March 4, 2020

Loading...
Loading...

Upgrades

  • Wedbush changed the rating for AGNC Investment Corp AGNC from Neutral to Outperform. In the fourth quarter, AGNC Investment showed an EPS of $0.57, compared to $0.53 from the year-ago quarter. The stock has a 52-week-high of $19.65 and a 52-week-low of $14.51. AGNC Investment's stock last closed at $17.88 per share.
  • B. Riley FBR upgraded the stock for International Seaways Inc INSW from Neutral to Buy. International Seaways earned $1.32 in the fourth quarter, compared to $0.32 in the year-ago quarter. The stock has a 52-week-high of $31.39 and a 52-week-low of $15.15. International Seaways's stock last closed at $20.57 per share.
  • For AptarGroup Inc ATR, Wells Fargo upgraded the stock from Equal-Weight to Overweight. For the fourth quarter, AptarGroup had an EPS of $0.80, compared to year-ago quarter EPS of $0.92. The stock has a 52-week-high of $126.19 and a 52-week-low of $99.21. AptarGroup's stock last closed at $102.62 per share.
  • B of A Securities changed the rating for Highwoods Properties Inc HIW from Neutral to Buy. Highwoods Properties earned $0.91 in the fourth quarter, compared to $0.86 in the year-ago quarter. The stock has a 52-week-high of $52.76 and a 52-week-low of $40.75. Highwoods Properties's stock last closed at $46.60 per share.
  • Janney Capital upgraded the stock for American States Water Co AWR from Neutral to Buy. American States Water earned $0.45 in the fourth quarter, compared to $0.37 in the year-ago quarter. The stock has a 52-week-high of $96.00 and a 52-week-low of $67.52. American States Water's stock last closed at $81.07 per share.
  • First Analysis changed the rating for Proofpoint Inc PFPT from Outperform to Strong Buy. Proofpoint earned $0.52 in the fourth quarter, compared to $0.51 in the year-ago quarter. The stock has a 52-week-high of $133.58 and a 52-week-low of $102.25. Proofpoint's stock last closed at $107.40 per share.
  • Nomura changed the rating for The Home Depot Inc HD from Neutral to Buy. Home Depot earned $2.28 in the fourth quarter, compared to $2.25 in the year-ago quarter. The stock has a 52-week-high of $247.36 and a 52-week-low of $179.52. Home Depot's stock last closed at $227.93 per share.
  • Societe Generale upgraded the stock for Oracle Corp ORCL from Hold to Buy. For the second quarter, Oracle had an EPS of $0.90, compared to year-ago quarter EPS of $0.80. The stock has a 52-week-high of $60.50 and a 52-week-low of $47.90. Oracle's stock last closed at $48.86 per share.
  • Citigroup changed the rating for Morgan Stanley MS from Neutral to Buy. Morgan Stanley earned $1.20 in the fourth quarter, compared to $0.73 in the year-ago quarter. The stock has a 52-week-high of $57.57 and a 52-week-low of $38.76. Morgan Stanley's stock last closed at $44.39 per share.
  • JP Morgan changed the rating for Arista Networks Inc ANET from Underweight to Neutral. For the fourth quarter, Arista Networks had an EPS of $2.29, compared to year-ago quarter EPS of $2.25. The stock has a 52-week-high of $331.27 and a 52-week-low of $173.31. Arista Networks's stock last closed at $191.66 per share.
  • B. Riley upgraded the stock for International Seaways Inc INSW from Neutral to Buy. In the fourth quarter, International Seaways showed an EPS of $1.32, compared to $0.32 from the year-ago quarter. The stock has a 52-week-high of $31.39 and a 52-week-low of $15.15. International Seaways's stock last closed at $20.57 per share.
  • For Chipotle Mexican Grill Inc CMG, Wells Fargo upgraded the stock from Equal-Weight to Overweight. In the fourth quarter, Chipotle Mexican Grill showed an EPS of $2.86, compared to $1.72 from the year-ago quarter. The stock has a 52-week-high of $940.28 and a 52-week-low of $604.64. Chipotle Mexican Grill's stock last closed at $735.80 per share.
  • KeyBanc changed the rating for Mattel Inc MAT from Sector Weight to Overweight. In the fourth quarter, Mattel showed an EPS of $0.11, compared to $0.04 from the year-ago quarter. The stock has a 52-week-high of $15.19 and a 52-week-low of $9.06. Mattel's stock last closed at $11.85 per share.

 

Downgrades

  • H.C. Wainwright downgraded the stock for SpringWorks Therapeutics Inc SWTX from Buy to Neutral. For the third quarter, SpringWorks Therapeutics had an EPS of ($1.77), compared to year-ago quarter EPS of ($11.55). The stock has a 52-week-high of $42.66 and a 52-week-low of $17.02. SpringWorks Therapeutics's stock last closed at $41.21 per share.
  • For Unum Therapeutics Inc UMRX, Wedbush downgraded the stock from Outperform to Neutral. For the second quarter, Unum Therapeutics had an EPS of ($0.34), compared to year-ago quarter EPS of ($0.31). The stock has a 52-week-high of $4.87 and a 52-week-low of $0.48. Unum Therapeutics's stock last closed at $0.53 per share.
  • For Okta Inc OKTA, Needham downgraded the stock from Buy to Hold. Okta earned ($0.07) in the third quarter, compared to ($0.04) in the year-ago quarter. The stock has a 52-week-high of $142.98 and a 52-week-low of $70.44. Okta's stock last closed at $131.34 per share.
  • Compass Point downgraded the stock for Atlantic Union Bankshares Corp AUB from Buy to Neutral. For the fourth quarter, Atlantic Union Bankshares had an EPS of $0.71, compared to year-ago quarter EPS of $0.70. The stock has a 52-week-high of $40.20 and a 52-week-low of $28.95. Atlantic Union Bankshares's stock last closed at $29.01 per share.
  • Compass Point downgraded the stock for Provident Bancorp Inc PVBC from Buy to Neutral. Provident Bancorp earned $0.14 in the fourth quarter, compared to $0.15 in the year-ago quarter. The stock has a 52-week-high of $28.46 and a 52-week-low of $10.75. Provident Bancorp's stock last closed at $10.99 per share.
  • Compass Point downgraded the stock for Independent Bank Corp INDB from Buy to Neutral. In the fourth quarter, Independent Bank showed an EPS of $1.38, compared to $1.29 from the year-ago quarter. The stock has a 52-week-high of $87.64 and a 52-week-low of $62.33. Independent Bank's stock last closed at $69.57 per share.
  • Compass Point changed the rating for First Hawaiian Inc FHB from Buy to Neutral. First Hawaiian earned $0.54 in the fourth quarter, compared to $0.58 in the year-ago quarter. The stock has a 52-week-high of $31.25 and a 52-week-low of $23.52. First Hawaiian's stock last closed at $24.20 per share.
  • Compass Point downgraded the stock for Western New England Bancorp Inc WNEB from Buy to Neutral. The stock has a 52-week-high of $10.15 and a 52-week-low of $8.50. Western New England's stock last closed at $8.60 per share.
  • Barclays downgraded the stock for Nordstrom Inc JWN from Equal-Weight to Underweight. For the fourth quarter, Nordstrom had an EPS of $1.42, compared to year-ago quarter EPS of $1.48. The stock has a 52-week-high of $48.87 and a 52-week-low of $25.01. Nordstrom's stock last closed at $33.43 per share.
  • For Forty Seven Inc FTSV, Mizuho downgraded the stock from Buy to Neutral. Forty Seven earned ($0.38) in the third quarter, compared to ($0.71) in the year-ago quarter. The stock has a 52-week-high of $94.68 and a 52-week-low of $5.53. Forty Seven's stock last closed at $94.24 per share.

 

Initiations

  • With a rating of Outperform, Raymond James initiated coverage on Dynatrace Inc DT. The price target is set at $38.00 for Dynatrace. In the third quarter, Dynatrace earned $0.10. The stock has a 52-week-high of $37.06 and a 52-week-low of $17.05. Dynatrace's stock last closed at $31.49 per share.
  • With a rating of Overweight, Barclays initiated coverage on Epizyme Inc EPZM. The price target is set at $33.00 for Epizyme. For the fourth quarter, Epizyme had an EPS of ($0.59), compared to year-ago quarter EPS of ($0.29). The stock has a 52-week-high of $27.82 and a 52-week-low of $9.73. Epizyme's stock last closed at $20.72 per share.
  • Barclays initiated coverage on Xencor Inc XNCR with an Underweight rating. The price target for Xencor is set at $28.00. Xencor earned ($0.47) in the fourth quarter, compared to ($0.32) in the year-ago quarter. The stock has a 52-week-high of $46.33 and a 52-week-low of $27.75. Xencor's stock last closed at $32.59 per share.
  • Barclays initiated coverage on Nektar Therapeutics NKTR with an Overweight rating. The price target for Nektar Therapeutics is set at $30.00. In the fourth quarter, Nektar Therapeutics showed an EPS of ($0.64), compared to ($0.57) from the year-ago quarter. The stock has a 52-week-high of $40.51 and a 52-week-low of $15.63. Nektar Therapeutics's stock last closed at $19.43 per share.
  • With a rating of Overweight, Barclays initiated coverage on Iovance Biotherapeutics Inc IOVA. The price target is set at $45.00 for Iovance Biotherapeutics. For the fourth quarter, Iovance Biotherapeutics had an EPS of ($0.50), compared to year-ago quarter EPS of ($0.27). The stock has a 52-week-high of $36.25 and a 52-week-low of $9.21. Iovance Biotherapeutics's stock last closed at $35.79 per share.
  • With a rating of Equal-Weight, Barclays initiated coverage on Agios Pharmaceuticals Inc AGIO. The price target is set at $50.00 for Agios Pharmaceuticals. For the fourth quarter, Agios Pharmaceuticals had an EPS of ($1.60), compared to year-ago quarter EPS of ($1.58). The stock has a 52-week-high of $68.94 and a 52-week-low of $28.36. Agios Pharmaceuticals's stock last closed at $46.78 per share.
  • With a rating of Underweight, Barclays initiated coverage on Macrogenics Inc MGNX. The price target is set at $8.00 for Macrogenics. Macrogenics earned ($0.62) in the fourth quarter, compared to ($1.06) in the year-ago quarter. The stock has a 52-week-high of $20.95 and a 52-week-low of $7.42. Macrogenics's stock last closed at $8.65 per share.
  • With a rating of Overweight, Barclays initiated coverage on Syndax Pharmaceuticals Inc SNDX. The price target is set at $15.00 for Syndax Pharmaceuticals. For the fourth quarter, Syndax Pharmaceuticals had an EPS of ($0.44), compared to year-ago quarter EPS of ($0.70). The stock has a 52-week-high of $11.33 and a 52-week-low of $4.52. Syndax Pharmaceuticals's stock last closed at $9.27 per share.
  • Barclays initiated coverage on Exelixis Inc EXEL with an Overweight rating. The price target for Exelixis is set at $26.00. Exelixis earned $0.26 in the fourth quarter, compared to $0.37 in the year-ago quarter. The stock has a 52-week-high of $25.31 and a 52-week-low of $15.02. Exelixis's stock last closed at $18.74 per share.
  • Barclays initiated coverage on Deciphera Pharmaceuticals Inc DCPH with an Overweight rating. The price target for Deciphera Pharmaceuticals is set at $70.00. In the third quarter, Deciphera Pharmaceuticals showed an EPS of ($1.28), compared to ($0.65) from the year-ago quarter. The stock has a 52-week-high of $71.11 and a 52-week-low of $19.88. Deciphera Pharmaceuticals's stock last closed at $56.04 per share.
  • With a rating of Overweight, Barclays initiated coverage on Arcus Biosciences Inc RCUS. The price target is set at $24.00 for Arcus Biosciences. For the third quarter, Arcus Biosciences had an EPS of ($0.51), compared to year-ago quarter EPS of ($0.25). The stock has a 52-week-high of $18.44 and a 52-week-low of $6.30. Arcus Biosciences's stock last closed at $16.65 per share.
  • Barclays initiated coverage on Fate Therapeutics Inc FATE with an Overweight rating. The price target for Fate Therapeutics is set at $40.00. Fate Therapeutics earned ($0.37) in the fourth quarter, compared to ($0.25) in the year-ago quarter. The stock has a 52-week-high of $32.39 and a 52-week-low of $12.59. Fate Therapeutics's stock last closed at $28.25 per share.
  • With a rating of Overweight, Barclays initiated coverage on Karyopharm Therapeutics Inc KPTI. The price target is set at $30.00 for Karyopharm Therapeutics. In the fourth quarter, Karyopharm Therapeutics showed an EPS of ($0.76), compared to ($0.96) from the year-ago quarter. The stock has a 52-week-high of $29.61 and a 52-week-low of $3.92. Karyopharm Therapeutics's stock last closed at $24.68 per share.
  • Piper Sandler initiated coverage on Qualcomm Inc QCOM with a Neutral rating. The price target for Qualcomm is set at $80.00. For the first quarter, Qualcomm had an EPS of $0.99, compared to year-ago quarter EPS of $1.20. The stock has a 52-week-high of $96.17 and a 52-week-low of $53.03. Qualcomm's stock last closed at $78.56 per share.
  • Cantor Fitzgerald initiated coverage on ZIOPHARM Oncology Inc ZIOP with an Overweight rating. The price target for ZIOPHARM Oncology is set at $6.00. In the fourth quarter, ZIOPHARM Oncology showed an EPS of ($0.09), compared to ($0.08) from the year-ago quarter. The stock has a 52-week-high of $7.25 and a 52-week-low of $2.68. ZIOPHARM Oncology's stock last closed at $2.90 per share.
Loading...
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: UpgradesDowngradesInitiationIntraday UpdateAnalyst RatingsConsumer DiscretionaryInitiationsIntegrated Telecommunication ServicesLeisure ProductsTelecommunication Servicestop upgrades
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...